Antithrombin Rouen-II, a new inherited variant of antithrombin-III, was found in two members of a family with no definite history of thrombosis. The subjects had normal antigenic concentrations of antithrombin and normal progressive inhibitory activity. However, the variant had defective heparin and heparan sulfate cofactor activities, and was not activated by a synthetic pentasaccharide representing the minimum heparin sequence. The abnormal antithrombin was isolated using heparin-Sepharose chromatography, and on electrophoresis at pH 8.6 migrated more anodally than normal. Two-dimensional peptide mapping of tryptic and Staphylococcus aureus V8 protease digests was performed and the abnormal peptide was located by tryptophan staining. Amino acid sequence studies demonstrated a substitution of arginine at residue 47 by a serine. Evidence strongly suggests that arginine 47 is a prime heparin binding site in antithrombin and that it forms part of a proposed positively charged linear site (to which heparin binds) that stretches across the surface of the molecule from the A to the D helix.
J Y Borg, M C Owen, C Soria, J Soria, J Caen, R W Carrell
Title and authors | Publication | Year |
---|---|---|
Molecular Mechanisms of the Impaired Heparin Pentasaccharide Interactions in 10 Antithrombin Heparin Binding Site Mutants Revealed by Enhanced Sampling Molecular Dynamics
Balogh G, Bereczky Z |
Biomolecules | 2024 |
Polymeric Biomaterials: Medicinal and Pharmaceutical Applications, Volume 2
S Deshayes, K Gionnet, V Maurizot, G Déléris |
Polymeric Biomaterials: Medicinal and Pharmaceutical Applications, Volume 2 | 2013 |
Production of Plasma Proteins for Therapeutic Use: Bertolini/Plasma Proteins
S Chtourou, M Poulle |
Production of Plasma Proteins for Therapeutic Use: Bertolini/Plasma Proteins | 2012 |
Biomaterials Fabrication and Processing Handbook
LR Berry, AK Chan |
Biomaterials Fabrication and Processing Handbook | 2008 |
Women's Vascular Health
R Lindsay |
Women's Vascular Health | 2006 |
Chemistry and Biology of Heparin and Heparan Sulfate
JM Walenga, WP Jeske, J Fareed |
Chemistry and Biology of Heparin and Heparan Sulfate | 2005 |
Polymeric Biomaterials, Revised and Expanded
L Berry, M Andrew, A Chan |
Polymeric Biomaterials, Revised and Expanded | 2001 |
Hämostaseologie
G Müller-Berghaus, B Pötzsch |
Hämostaseologie | 1999 |
The anticoagulant activation of antithrombin by heparin
L Jin, JP Abrahams, R Skinner, M Petitou, RN Pike, RW Carrell |
Proceedings of the National Academy of Sciences | 1997 |
BIOCHEMICAL AND PHARMACOLOGIC RATIONALE FOR THE DEVELOPMENT OF A SYNTHETIC HEPARIN PENTASACCHARIDE
JM Walenga, WP Jeske, L Bara, MM Samama, J Fareed |
Thrombosis Research | 1997 |
The 2.6 Å structure of antithrombin indicates a conformational change at the heparin binding site
R Skinner, JP Abrahams, JC Whisstock, AM Lesk, RW Carrell, MR Wardell |
Journal of Molecular Biology | 1997 |
Chemistry and Biology of Serpins
FC Church, DD Cunningham, D Ginsburg, M Hoffman, SR Stone, DM Tollefsen |
1997 | |
Review
M Epstein |
Renal Failure | 1996 |
Molecular genetics of human antithrombin deficiency
DJ Perry, RW Carrell |
Human Mutation | 1996 |
Molecular genetics of antithrombin deficiency
DA Lane, G Kunz, RJ Olds, SL Thein |
Blood Reviews | 1996 |
Role of Arginine 132 and Lysine 133 in Heparin Binding to and Activation of Antithrombin
JL Meagher, JA Huntington, B Fan, PG Gettins |
The Journal of biological chemistry | 1996 |
Cardiovascular Science in France
K Schwartz, M Aiach |
Trends in Cardiovascular Medicine | 1996 |
Antithrombins Southport (Leu 99 to Val) and Vienna (Cln 118 to Pro): two novel antithrombin variants with abnormal heparin binding
V Chowdhury, B Mille, RJ Olds, DA Lane, J Watton, TW Barrowcliffe, I Pabinger, BE Woodcock, SL Thein |
British Journal of Haematology | 1995 |
What do dysfunctional serpins tell us about molecular mobility and disease?
PE Stein, RW Carrell |
Nature Structural Biology | 1995 |
Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin
WP Sheffield, MA Blajchman |
FEBS Letters | 1995 |
Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the .beta.-antithrombin III isoform with enhanced heparin affinity
V Picard, E Ersdal-Badju, SC Bock |
Biochemistry | 1995 |
THE MOLECULAR GENETICS OF ANTITHROMBIN DEFICIENCY
RJ Olid, D A.Lane, SL Thein |
British Journal of Haematology | 1994 |
Antithrombin and its inherited deficiencies
DJ Perry |
Blood Reviews | 1994 |
Conformational Change in Antithrombin Induced by Heparin, Probed with a Monoclonal Antibody against the 1C/4B Region
J Dawes, K James, DA Lane |
Biochemistry | 1994 |
Arg-129 plays a specific role in the confirmation of antithrombin and in the enhancement of factor Xa inhibition by the pentasaccharode sequence of heparin
S Najjam, G Chadeuf, S Gandrille, M Aiach |
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease | 1994 |
Three novel mutations of antithrombin inducing high-molecular-mass compounds
J Emmerich, D Vidaud, M Alhenc-Gelas, G Chadeuf, M Gouault-Heilmann, MF Aillaud, M Aiach |
Arteriosclerosis Thrombosis and Vascular Biology | 1994 |
Role of N- and C-terminal amino acids in antithrombin binding to pentasaccharide
B Mille, J Watton, TW Barrowcliffe, JC Mani, DA Lane |
The Journal of biological chemistry | 1994 |
Heparin binding affinity of normal and genetically modified antithrombin III measured using a monoclonal antibody to the heparin binding site of antithrombin III
J Watton, C Longstaff, DA Lane, TW Barrowcliffe |
Biochemistry | 1993 |
Pleiotropic effects of antithrombin strand 1C substitution mutations
DA Lane, RJ Olds, J Conard, M Boisclair, SC Bock, M Hultin, U Abildgaard, H Ireland, E Thompson, G Sas |
Journal of Clinical Investigation | 1992 |
Serpins: Mobile conformations in a family of proteinase inhibitors
RW Carrell, DL Evans |
Current Opinion in Structural Biology | 1992 |
Antithrombin Budapest 3 An antithrombin variant with reduced heparin affinity resulting from the substitution L99F
RJ Olds, DA Lane, M Boisclair, G Sas, SC Bock, SL Thein |
FEBS Letters | 1992 |
Expression and mutagenesis of thrombospondin
J Lawler, P Ferro, M Duquette |
Biochemistry | 1992 |
Heparin binding site, conformational change, and activation of antithrombin
DL Evans, CJ Marshall, PB Christey, RW Carrell |
Biochemistry | 1992 |
Cerebral infarction in a heterozygote with variant antithrombin III
T Arima, M Motomura, Y Nishiura, M Tsujihata, K Okajima, H Abe, S Nagataki |
Stroke; a journal of cerebral circulation | 1992 |
Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin
HJ Ehrlich, RK Gebbink, J Keijer, H Pannekoek |
The Journal of biological chemistry | 1992 |
Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor
I Björk, K Ylinenjärvi, ST Olson, PE Bock |
The Journal of biological chemistry | 1992 |
Role of tryptophan 49 in the heparin cofactor activity of human antithrombin III
P Gettins, J Choay, BC Crews, G Zettlmeiss |
The Journal of biological chemistry | 1992 |
The molecular genetics of familial venous thrombosis
DN Cooper |
Blood Reviews | 1991 |
Novel point mutations leading to type 1 antithrombin deficiency and thrombosis
RJ Olds, DA Lane, H Ireland, G Leone, VD Stefano, ML Wiesel, JP Cazenave, SL Thein |
British Journal of Haematology | 1991 |
Antithrombin III-Amiens: A new family with an Arg47 → cys inherited variant of antithrombin iii with impaired heparin cofactor activity
B Roussel, J Dieval, J Delobel, F Fernandez-Rachubinski, B Eng, RA Rachubinski, MA Blajchman |
American Journal of Hematology | 1991 |
P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase Implications for the heparin activation mechanism
MC Owen, PM George, DA Lane, DR Boswell |
FEBS Letters | 1991 |
The tammar wallaby major plasma serpin: Partial characterization including the sequence of the reactive site region
SD Patterson, K Bell, DC Shaw |
Comparative Biochemistry and Physiology Part C: Comparative Pharmacology | 1991 |
Functional antithrombin-III variant (41 pro→leu) identified by liquid secondary ion mass spectrometry
SO Brennan, JY Borg, GJ Shaw, J Caen, PM George |
Pathology | 1991 |
Recombinant Technology in Hemostasis and Thrombosis
LW Hoyer, WN Drohan |
1991 | |
Role of lysine 173 in heparin binding to heparin cofactor II
HC Whinna, MA Blinder, M Szewczyk, DM Tollefsen, FC Church |
The Journal of biological chemistry | 1991 |
Clinical and biochemical characterization of antithrombin III Franconville, a variant with Pro 41 Leu mutation
N Roux, G Chadeuf, P Molho-Sabatier, PF Plouin, M Aiach |
British Journal of Haematology | 1990 |
Antithrombin III: structural and functional aspects
L Mourey, JP Samama, M Delarue, J Choay, JC Lormeau, M Petitou, D Moras |
Biochimie | 1990 |
Antithrombin Rouen-IV 24 Arg→Cys The amino-terminal contribution to heparin binding
JY Borg, SO Brennan, RW Carrell, P George, DJ Perry, J Shaw |
FEBS Letters | 1990 |
Antithrombin III
CH Beresford, MC Owen |
International Journal of Biochemistry | 1990 |
Interaction of factor Xa with heparin does not contribute to the inhibition of factor Xa by antithrombin III-heparin
BA Owen, WG Owen |
Biochemistry | 1990 |
New Trends in Haemostasis
J Harenberg, DL Heene, G Stehle, G Schettler |
1990 | |
Important role of arginine 129 in heparin-binding site of antithrombin III. Identification of a novel mutation arginine 129 to glutamine
S Gandrille, M Aiach, DA Lane, D Vidaud, P Molho-Sabatier, R Caso, P de Moerloose, JN Fiessinger, E Clauser |
The Journal of biological chemistry | 1990 |
Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight Heparins:
M Verstraete |
Drugs | 1990 |
Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation
P Molho-Sabatier, M Aiach, I Gaillard, JN Fiessinger, AM Fischer, G Chadeuf, E Clauser |
Journal of Clinical Investigation | 1989 |
9 Antithrombin: Structure, genomic organization, function and inherited deficiency
DA Lane, R Caso |
Baillière's Clinical Haematology | 1989 |
Implications of the three-dimensional structure of .alpha.1-antitrypsin for structure and function of serpins
R Huber, RW Carrell |
Biochemistry | 1989 |
Heparin Cofactor IIOslo
MA Blinder, TR Andersson, U Abildgaard, DM Tollefsen |
The Journal of biological chemistry | 1989 |
Antithrombin Activity of Fucoidan
FC Church, JB Meade, RE Treanor, HC Whinna |
The Journal of biological chemistry | 1989 |
A novel amino acid substitution in the reactive site of a congenital variant antithrombin
DA Lane, H Erdjument, E Thompson, M Panico, VD Marzo, HR Morris, G Leone, VD Stefano, SL Thein |
The Journal of biological chemistry | 1989 |
New carbohydrate site in mutant antithrombin (7 Ile→Asn) with decreased heparin affinity
SO Brennan, JY Borg, PM George, C Soria, J Soria, J Caen, RW Carrell |
FEBS Letters | 1988 |
Thrombin
JW Fenton |
Annals of the New York Academy of Sciences | 1986 |